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recommendation has been classiﬁed as ‘2’, meaning that the
majority of people in this situation would want the
recommended course of action, but many would not, and
different choices will be appropriate for different patients. The
quality of the studies used for this recommendation was
classiﬁed as ‘C’, indicating that it was low. This means that the
true effect may be substantially different from the estimate of
the effect.
The authors mention that many studies have shown a close
association between serum phosphorus concentration and the
relative risk of mortality. Based on these observations, and
their data demonstrating an association of vascular calciﬁca-
tion with serum phosphorus concentrations of 4.8mg/dl or
greater, they claim that the serum phosphorus levels should be
normalized in patients with CKD stage 5D. As pointed out in
our CKD-MBD guideline, it is impossible to draw ﬁrm
conclusions from association studies, because they are only
hypothesis generating. There are several examples in recent
literature wherein randomized controlled trials did not
conﬁrm the results of observational studies in patients with
CKD, as for example with anemia correction or cholesterol
lowering.3 It is also not clear whether slowing vascular
calciﬁcation translates into improvements in clinical out-
comes, and therefore this should be considered as a surrogate
end point only and should not supersede conclusions from
associative mortality studies.
To date, there is no convincing report showing that the
active normalization of hyperphosphatemia with any therapy
(phosphate binders, diet, or dialysis) improves hard patient
outcomes such as fractures, cardiovascular events or death.
Thus, although the experimental evidence that phosphorus is
a uremic toxin is strong,4 deﬁnitive human data are lacking.
Therefore, although it is reasonable to lower serum
phosphorus levels towards normal, caregivers must weigh
any potential beneﬁt against the potential adverse conse-
quences of such an approach for a given patient.5
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Proposed controlled trials of
phosphate reduction in CKD:
which whey should we go?
To the Editor: Isakova et al.1 have written an outstanding
review of the potential importance of phosphate as a uremic
toxin in many organ systems, and justiﬁably cite the need for
randomized controlled trials in this area. However, their
proposed trial designs primarily emphasize the testing of various
phosphate binders, with diet being relegated to a secondary role.
Even a hefty dose of binder will remove only about 200–300mg/
day of phosphate,2,3 whereas phosphate intake is commonly in
the range of 1–1.5 g/day, of which about 70% is normally
absorbed. There is some degree of nihilism in this area with
regard to dietary counseling, although compliance with very-
low-protein diets may not be that difﬁcult for a substantial
number of patients.4 Furthermore, phosphate intake can to a
substantial extent be decoupled from protein intake. Murphy-
Gutekunst and Uribarri5 have reviewed the many sources of
industry-added phosphate to foods, including processed meats,
cereals, and soft drinks, and Sherman and Mehta6 have
emphasized the variability of the phosphate to protein ratio.
Boiling of meat can reduce its phosphate content substantially,
while maintaining most of its nitrogen content.7 Finally,
powdered whey protein is a cheap dietary supplement widely
available in health food stores and gymnasiums. Although the
phosphate content of whey varies, a typical composition may be
56mg of phosphate in 25 g (2.24mg/g) of very high biological
value protein (TwinLab 100% Whey Protein Fuel, Ideasphere,
American Fork, UT, USA). Methods for formulating low-
phosphorus whey protein hydrolysates have been described,
which produce a product containing as little as 0.15mg
phosphorus per gram of protein.8 A dose of 50 g/day of protein
supplement as commercially available powdered whey would
deliver only 100–200mg/day of phosphorus. This, coupled with
a 0.3 g/kg/day low-protein diet, with special attention to
avoidance of foods with a high phosphorus/protein ratio, should
be able to reduce the dietary phosphate intake from 1–1.5 g/day
to the range of 500–600mg/day, while maintaining amino-acid
needs. The use of whey protein in uremia is not a new idea,9 but
is one that might bear revisiting in more modern circumstances.
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The Authors Reply: We thank Daugirdas for his comments
in ‘Proposed controlled trials of phosphate reduction in CKD:
which whey should we go?’1 We agree that reducing dietary
phosphorus intake is an important strategy to control
phosphorus balance in renal failure that is worthy of testing
in randomized trials. Daugirdas’s interesting approach would
effectively dissociate phosphorus restriction from undesirable
protein restriction through the use of whey supplements and
through avoidance of foods with high phosphorus-to-protein
ratios, such as processed foods. In support of this proposal,
the feasibility of dietary counseling to reduce serum
phosphate levels in dialysis patients has been established by
a recent randomized trial.2 It is likely, however, that several
factors could limit the effectiveness and sustainability of
dietary phosphorus restriction alone. First, the lack of
accurate labeling of phosphorus content in food additives
and its inconsistency across speciﬁc manufacturers3 compli-
cates dietary counseling. Second, while the cost of whey may
be low, effective ongoing dietary counseling requires dedi-
cated and relatively costly nutritionists. Perhaps most
importantly, kidney disease is largely a disease of poverty,
which, under the strain of the recession, is deepening in the
United States. Impoverished dialysis patients, even those most
successfully counseled, will likely forgo healthy food choices
in favor of cheap prepared foods that are phosphorus-laden
and widely available. To beneﬁt the majority of patients, we
would therefore suggest a multipronged approach to reduce
phosphate levels in dialysis patients, involving both pharma-
ceutical and dietary interventions as suggested by Daugirdas.
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Non-infected hemodialysis
catheters are associated with
increased inflammation compared
with arteriovenous fistulas
To the Editor: We read with great interest the article by
Goldstein et al.,1 reporting that catheters may cause
inﬂammation independent of infection as compared with
arteriovenous (AV) ﬁstula use. The authors showed greater
levels of serum C-reactive protein (CRP) in patients dialyzed
with central catheters in contrast to AV ﬁstulas.
We wish to highlight a few important points. First, the
authors did not give any information about comorbidity status,
underlying primary renal disease, level of uremia, glycemic
control of diabetic patients, echocardiographic data, anthro-
pometric measures, or prealbumin and cholesterol concentra-
tions showing nutritional status and residual renal function
(RRF) at the start of hemodialysis. It is known that CRP is
affected not only by infection but also by many variables, such
as RRF, coronary heart disease, peripheral arterial disease,
malnutrition, and metabolic syndrome.2,3 Thus, it is very
difﬁcult to attribute high CRP levels solely to the presence of a
catheter unless these variables are appropriately controlled for.
Second, the authors measured only serum CRP concentra-
tions, did not include other inﬂammation markers, and took
measurements just twice in a 6-month period. CRP levels,
especially in the hemodialysis population, may ﬂuctuate; thus,
obtaining single CRP measurements may be misleading.4
Third, the catheter group involved desperate patients in
whom ﬁstula attempt had failed. Thus, there was no option
other than catheter use, of course after trying the ﬁstula at a
more proximal site and vascular grafts. The advantages of the
‘ﬁstula ﬁrst’ slogan have long been established for naive
patients. Hence, a call for ﬁstula ﬁrst for patients with failed
ﬁstulas seems inappropriate.
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